Literature DB >> 30301839

LPA4-Mediated Vascular Network Formation Increases the Efficacy of Anti-PD-1 Therapy against Brain Tumors.

Daisuke Eino1,2,3, Yohei Tsukada1, Hisamichi Naito1, Yonehiro Kanemura4, Tomohiro Iba1, Taku Wakabayashi1, Fumitaka Muramatsu1, Hiroyasu Kidoya1, Hideyuki Arita2, Naoki Kagawa2, Yasunori Fujimoto2, Kazuhiro Takara1,5, Haruhiko Kishima2, Nobuyuki Takakura6.   

Abstract

: The structure and function of tumor blood vessels profoundly affects the tumor microenvironment. Signals mediated through the lysophosphatidic acid receptor 4 (LPA4) promote vascular network formation to restore normal vascular barrier function in subcutaneous tumors and thus improve drug delivery. However, the characteristics of the vasculature vary by organ and tumor types, and how drug delivery and leukocyte trafficking are affected by modification of vascular function by LPA in different cancers is unclear. Here, we show that LPA4 activation promotes the formation of fine vascular structures in brain tumors. RhoA/ROCK signaling contributed to LPA-induced endothelial cell-cell adhesion, and RhoA/ROCK activity following LPA4 stimulation regulated expression of VCAM-1. This resulted in increased lymphocyte infiltration into the tumor. LPA improved delivery of exogenous IgG into brain tumors and enhanced the anticancer effect of anti-programmed cell death-1 antibody therapy. These results indicate the effects of LPA on vascular structure and function apply not only to chemotherapy but also to immunotherapy. SIGNIFICANCE: These findings demonstrate that lysophosphatidic acid, a lipid mediator, promotes development of a fine capillary network in brain tumors by inducing tightening of endothelial cell-to-cell adhesion, facilitating improved drug delivery, and lymphocyte penetration. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30301839     DOI: 10.1158/0008-5472.CAN-18-0498

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  LPA receptor 4 deficiency attenuates experimental atherosclerosis.

Authors:  Liping Yang; Maria Kraemer; Xianjun Frank Fang; Peggi M Angel; Richard R Drake; Andrew J Morris; Susan S Smyth
Journal:  J Lipid Res       Date:  2019-02-22       Impact factor: 5.922

2.  Anti-cancer strategies targeting the autotaxin-lysophosphatidic acid receptor axis: is there a path forward?

Authors:  Gábor Tigyi; Mélanie A Dacheux; Kuan-Hung Lin; Junming Yue; Derek Norman; Zoltán Benyó; Sue Chin Lee
Journal:  Cancer Metastasis Rev       Date:  2021-03       Impact factor: 9.264

3.  An in vivo model allowing continuous observation of human vascular formation in the same animal over time.

Authors:  Yohei Tsukada; Fumitaka Muramatsu; Yumiko Hayashi; Chiaki Inagaki; Hang Su; Tomohiro Iba; Hiroyasu Kidoya; Nobuyuki Takakura
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

Review 4.  Role of lysophosphatidic acid and its receptors in health and disease: novel therapeutic strategies.

Authors:  Luiz Henrique Medeiros Geraldo; Tânia Cristina Leite de Sampaio Spohr; Rackele Ferreira do Amaral; Anna Carolina Carvalho da Fonseca; Celina Garcia; Fabio de Almeida Mendes; Catarina Freitas; Marcos Fabio dosSantos; Flavia Regina Souza Lima
Journal:  Signal Transduct Target Ther       Date:  2021-02-01

Review 5.  Vascular reconstitution in the tumor for more effective tumor immunotherapy.

Authors:  Nobuyuki Takakura
Journal:  Cancer Sci       Date:  2021-03-03       Impact factor: 6.716

Review 6.  Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade.

Authors:  Min Zhang; Kehai Liu; Mingfu Wang
Journal:  RSC Adv       Date:  2019-10-22       Impact factor: 4.036

7.  Understanding modulations of lipid mediators in cancer using a murine model of carcinomatous peritonitis.

Authors:  Makoto Kurano; Eri Sakai; Yutaka Yatomi
Journal:  Cancer Med       Date:  2022-03-22       Impact factor: 4.711

8.  Endothelial cell-derived Apelin inhibits tumor growth by altering immune cell localization.

Authors:  Liuying Hu; Yumiko Hayashi; Hiroyasu Kidoya; Nobuyuki Takakura
Journal:  Sci Rep       Date:  2021-07-07       Impact factor: 4.379

Review 9.  Alliance with EPR Effect: Combined Strategies to Improve the EPR Effect in the Tumor Microenvironment.

Authors:  Jooho Park; Yongwhan Choi; Hyeyoun Chang; Wooram Um; Ju Hee Ryu; Ick Chan Kwon
Journal:  Theranostics       Date:  2019-10-17       Impact factor: 11.556

Review 10.  Lysophosphatidic Acid Receptor Antagonists and Cancer: The Current Trends, Clinical Implications, and Trials.

Authors:  Yu-Hsuan Lin; Yueh-Chien Lin; Chien-Chin Chen
Journal:  Cells       Date:  2021-06-29       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.